Literature DB >> 7640155

Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma.

S A Corlett1, D Parker, H Chrystyn.   

Abstract

Ifosfamide is a chiral pro-drug which is administered clinically in its racemic form. Serum concentrations of rac-ifosfamide and its enantiomers were measured in 12 patients with lung carcinoma following a mean (+/- s.d.) intravenous dose of 4.2 (0.83) g infused over 1 h. The mean (+/- s.d.) volumes of distribution (VSS) of rac, (R)- and (S)-ifosfamide were 0.61 (0.17), 0.60 (0.16) and 0.61 (0.19) l kg-1, respectively. The mean (+/- s.d.) half-lives and clearances were 6.57 (1.69), 7.12 (1.92) and 5.98 (1.52) h and 0.065 (0.013), 0.060 (0.013) and 0.072 (0.014) l h-1 kg-1 for rac, (R)- and (S)-ifosfamide, respectively. The half-life of (S)-ifosfamide was significantly (P < 0.001) shorter than that of (R)-ifosfamide and it had a significantly higher clearance (P < 0.001). There was no significant difference in the volumes of distribution of the enantiomers. The clinical significance of the faster elimination of (S)-ifosfamide is not known.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640155      PMCID: PMC1365136          DOI: 10.1111/j.1365-2125.1995.tb04477.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The pharmacokinetics of ifosfamide given as short and long intravenous infusions in cancer patients.

Authors:  L D Lewis; D L Fitzgerald; P Mohan; N Thatcher; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

2.  The effect of age on the pharmacokinetics of ifosfamide.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1990-07       Impact factor: 4.335

3.  Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

4.  Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.

Authors:  M J Lind; J M Margison; T Cerny; N Thatcher; P M Wilkinson
Journal:  Cancer Res       Date:  1989-02-01       Impact factor: 12.701

5.  Fractionated ifosfamide therapy produces a time-dependent increase in ifosfamide metabolism.

Authors:  L D Lewis; D L Fitzgerald; P G Harper; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1990-11       Impact factor: 4.335

6.  Urinary excretion of the enantiomers of ifosfamide and its inactive metabolites in children.

Authors:  J Boos; U Welslau; J Ritter; G Blaschke; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide.

Authors:  D Walker; J P Flinois; S C Monkman; C Beloc; A V Boddy; S Cholerton; A K Daly; M J Lind; A D Pearson; P H Beaune
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

8.  Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.

Authors:  A V Boddy; S M Yule; R Wyllie; L Price; A D Pearson; J R Idle
Journal:  Cancer Res       Date:  1993-08-15       Impact factor: 12.701

Review 9.  Ifosfamide pharmacokinetics.

Authors:  L D Lewis
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

10.  Enantiomeric separation of R- and S-ifosfamide and their determination in serum from clinical subjects.

Authors:  S A Corlett; H Chrystyn
Journal:  J Chromatogr B Biomed Appl       Date:  1994-03-18
View more
  4 in total

Review 1.  Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.

Authors:  T Kerbusch; J de Kraker; H J Keizer; J W van Putten; H J Groen; R L Jansen; J H Schellens; J H Beijnen
Journal:  Clin Pharmacokinet       Date:  2001-01       Impact factor: 6.447

Review 2.  Metabolism and pharmacokinetics of oxazaphosphorines.

Authors:  A V Boddy; S M Yule
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

3.  Stereoselective pharmacokinetics of ifosfamide in male and female rats.

Authors:  J J Wang; H Lu; K K Chan
Journal:  AAPS PharmSci       Date:  2000

4.  Stereoselective pharmacokinetics of ifosfamide and its 2- and 3-N-dechloroethylated metabolites in female cancer patients.

Authors:  C P Granvil; J Ducharme; B Leyland-Jones; M Trudeau; I W Wainer
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.